Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

TEAD inhibitor VT3989

An orally bioavailable, small molecule inhibitor of the auto-palmitoylation of the transcription factor TEAD (TEA domain), with potential antineoplastic activity. Upon oral administration, TEAD inhibitor VT3989 inhibits TEAD auto-palmitoylation, thereby disrupting the interaction between the transcription co-activators yes-associated protein 1 (YAP)/transcriptional coactivator with PDZ-binding motif (TAZ) and TEAD. This may inhibit YAP/TAZ-TEAD promoted gene transcription involved in tumor cell proliferation and survival. The Hippo-YAP/TAZ-TEAD pathway is dysregulated in certain cancers and diseases.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:TEAD auto-palmitoylation inhibitor VT3989
Code name:VT 3989
VT-3989
VT3989
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search